Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)

Author:

Punt C.J.A.,Fumoleau P.,van de Walle B.,Faber M.N.,Ravic M.,Campone M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference5 articles.

1. Discovery of novel antitumor sulfonamides targeting GI phase of the cell cycle;Owa;J Med Chem,1999

2. Phase I and pharmacokinetic study of E7070, a novel sulphonamide, given daily × 5 every three weeks as a one-hour infusion in patients with advanced solid tumors;Punt;Proc Am Assoc Cancer Res,2000

3. Phase I and pharmacokinetic study of E7070, a new chloro-indolylsulfonamide, given as a one-hour infusion every three weeks in patients with advanced solid tumors;Raymond;Proc Am Assoc Cancer Res,2000

4. Phase I and pharmucokinetic study of E7070 in patients with solid tumors as single IV infusion, weekly × 4, Q six weeks;Dittrich;Proc Am Assoc Cancer Res,2000

5. Phase I Inal of five-days continuous infusion E7070 [N(3-chloro 7 indolyl)-l,4 benzene-disulfonamide] in patients with solid tumors;Droz;Proc Am Assoc Cancer Res,2000

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3